

## Amgen Inc. IMDELLTRA History of Development References

[Ahn MJ, et al.](#) Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. *N Engl J Med*. 2023;389(22): 2063-2075.

[Giffin MJ, et al.](#) AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. *Clin Cancer Res*. 2021;27(5):1526-1537.

[Paz-Ares L, et al.](#) Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. *J Clin Oncol*. 2023;41(16):2893-2903.

[Sands J, et al.](#) Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up. *Journal of Thoracic Oncology*. OA10.03. 2024;19(10):S30 - S31.

[Ready N, et al.](#) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. *J Thorac Oncol*. 2019;14: 237-44.

[Chung HC, et al.](#) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol*. 2020;15: 618-27.

[von Pawel J, et al.](#) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol*. 1999;17:658-667.

[von Pawel J, et al.](#) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol*. 2014;32:4012-4019.

[Trigo J, et al.](#) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020;21:645-654.

[FDA Approval Announcement](#): U.S. Food and Drug Administration (FDA) website --- IMDELLTRA® (tarlatamab) approval, May 16, 2024.